Lantheus Holdings, Inc.

LNTH

Explore Our Financial Data > Companies > Lantheus Holdings, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	LNTH
CIK	0001521036
SIC	2835
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	In Vitro, In Vivo Diagnostic Substances

Contact

Address	331 TREBLE COVE ROAD, NORTH BILLERICA, MA, 01862
Website	lantheus.com
Phone	978 671-8001
CEO	Mary A. Heino
Employees	700

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$4.57 million
Pre-Tax Income	$373.67 million
Net Income	$279.03 million
Net Income to Common	$279.03 million
EPS	$4.19

View All

Balance Sheet

Cash	$498.58 million
Assets	$2.35 billion
Liabilities	$1.13 billion
Common Equity	$1.21 billion
Liabilities & Equity	$2.35 billion

View All

Cash Flow Statement

Net Income	$279.03 million
Cash From Operating Activities	$407.70 million
Cash From Investing Activities	$-537.46 million
Cash From Financing Activities	$-309.99 million
Change in Cash	$-439.92 million

View All

Calculations

NOPAT	$216.62 million
EBITDA	$455.94 million
Price to Earnings	$23.17
Price to Book	$5.33
ROE	23.48%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Lantheus to Present at the William Blair 46th Annual Growth Stock Conference

BEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3. To access the live webcast of t

Article Link

How The Story On Lantheus Holdings (LNTH) Is Shifting With PYLARIFY And Pipeline Expectations

Lantheus Holdings is back in focus after analysts lifted their fair value estimate from US$93.92 to US$104.08 per share. That change comes alongside generally constructive research coverage that leans on the Q4 update, PYLARIFY, and the broader radiopharmaceutical pipeline as key pieces of the story. Read on to see what is driving the shifting analyst narrative and how you can follow this evolving view over time. Analyst Price Targets don't always capture the full story. Head over to our...

Article Link

Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting

BEDFORD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced new radiodiagnostic data to be presented at the 2026 Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, taking place May 30 – June 2, 2026 in Los Angeles, CA. Presentation details are as follows: Date & Time: Monday

Article Link

Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

BEDFORD, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago, IL. Presentation details are as follows: Date & Time: Monday, June 1 Session Type: Poster Sessio

Article Link

3 Hyped Up Stocks with Warning Signs

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

Article Link